alexa Sustained Efficacy of Cetuximab after Therapy Discontinuation in a Patient with Advanced Colorectal Cancer
ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Sustained Efficacy of Cetuximab after Therapy Discontinuation in a Patient with Advanced Colorectal Cancer

Gerardo Rosati1*, Enrico Scarano2, Antonio Avallone3 and Domenico Bilancia1

1Medical Oncology Unit, “S. Carlo” Hospital of Potenza, Italy

2Radiology Unit, “S. Carlo” Hospital of Potenza, Italy

3Department of Gastrointestinal Medical Oncology, National Cancer Institute of Naples, Italy

*Corresponding Author:
Dr Gerardo Rosati
Medical Oncology Unit, “S. Carlo” Hospital of Potenza
Via Sanremo 197, 85100 Potenza, Italy
Tel: +39-0971-612273
Fax: +39-0971-613000
E-mail: [email protected]

Received date: January 04, 2014; Accepted date: March 28, 2014; Published date: May 07, 2014

Citation: Rosati G, Scarano E, Avallone A, Bilancia D (2014) Sustained Efficacy of Cetuximab after Therapy Discontinuation in a Patient with Advanced Colorectal Cancer . J Carcinog Mutagen S10:004. doi: 10.4172/2157-2518.S10-004

Copyright: © 2014 Rosati G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

In pivotal phase II and III studies, the targeting monoclonal antibody cetuximab has been shown to improve the efficacy of standard chemotherapy regimens used in first-line treatment of metastatic colorectal cancer. Safety data analyses from these studies indicate that cetuximab plus chemotherapy appears to be associated with a higher incidence of grade 3-4 adverse events than chemotherapy alone. In particular, dermatological toxicity and skin reactions can require an early discontinuation therapy affecting clinical outcomes. Herein, we present one case which document a sustained long-lasting efficacy of cetuximab triggered by a presumable immune response after discontinuation of therapy, in order to focus on the possibility to suggest a different use of antibody.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords